Roche to present at ESMO « Kinase News

Blogroll
Tags

AstraZeneca aurora Avastin bayer Bcr-Abl bevacizumab BMS c-kit cetuximab EGFR ErbB-2 ErbB2 erbitux Exelixis Genentech GlaxoSmithKline Gleevec GSK HER1 HER2 IGF-1R Imatinib ImClone JAK2 kinase Merck-Serono Met mTOR multikinase Nexavar Novartis onyx PDGF Pfizer phase I Phase II phase iii PI3K Preclinical regulatory Research Roche sorafenib VEGF VEGFR2
Providing a resource for information on kinase inhibitors

Roche to present at ESMO

Posted on September 10, 2008 by crimsoncanary

Roche have announced that 100+ abstracts on Roche medicines will be presented at the upcoming European Society for Medical Oncology (ESMO) meeting.

Key presentations include:

* Data from AVAiL, confirming the use of Avastin as first line treatment in NSCLC
* Phase III data on continuation of Herceptin treatment
* Phase II data data on the use of Avastin in treating glioblastoma

Filed under: kinase | Tagged: Avastin, bevacizumab, Genentech, HER2, Herceptin, kinase, Phase II, phase iii, Roche, Trastuzumab, VEGF

« GSK and Cellzome sign strategic alliance to discover kinase-targeted therapeutics AstraZeneca publish series of cyclin-dependent kinase inhibitors »